SLN

Silence Therapeutics PLC

Add to Watchlist

Advanced Chart

6.280

+0.13(2.114%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

6.300

Open

6.200

VWAP

6.17

Vol

53.73K

Mkt Cap

889.82M

Low

6.030

Amount

331.43K

EV/EBITDA(TTM)

Total Shares

46.66M

90.17M

EV/OCF(TTM)

P/S(TTM)

8.08

Silence Therapeutics plc is a global clinical-stage biotechnology company engaged in transforming people’s lives by silencing diseases through precision-engineered medicines created with proprietary siRNA (short interfering RNA) technology. The Company leverages its mRNAi GOLD platform to create siRNAs designed to precisely target and silence disease-associated genes in the liver. The Company focuses on areas of high unmet medical need with programs advancing cardiovascular disease, hematology and rare diseases. Divesiran (SLN124) is its wholly owned siRNA product candidate designed to inhibit TMPRSS6 expression in the liver. Zerlasiran is a siRNA molecule designed for the treatment of cardiovascular disease associated with elevated Lp(a), a lipoprotein in the blood. In addition to its wholly owned clinical pipeline, it has a third siRNA product candidate from its mRNAi GOLD platform in Phase I development in an undisclosed indication through its collaboration with AstraZeneca.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q3

FY2025Q2

FY2025Q1

4.59M

+217.58%

4.59M

+497.18%

4.19M

-73.33%

Estimates Revision

The market is revising Downward the revenue expectations for Silence Therapeutics plc (SLN) for FY2025, with the revenue forecasts being adjusted by -29.97% over the past three months. During the same period, the stock price has changed by 78.92%.

Revenue Estimates for FY2025

Revise Downward

-29.97%

In Past 3 Month

Stock Price

Go Up

+78.92%

In Past 3 Month

5 Analyst Rating

497.13% Upside

Wall Street analysts forecast SLN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SLN is 37.50 USD with a low forecast of 15.00 USD and a high forecast of 75.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

5 Buy

0 Hold

0 Sell

Strong Buy

497.13% Upside

Current: 6.280

Low

15.00

Averages

37.50

High

75.00

497.13% Upside

Current: 6.280

Low

15.00

Averages

37.50

High

75.00

HC Wainwright & Co.

Patrick Trucchio

Strong Buy

Reiterates

$75

2025-03-07

Reason

HC Wainwright & Co.

Patrick Trucchio

Price Target

$75

2025-03-07

Reiterates

Strong Buy

Reason

Morgan Stanley

Michael Ulz

Buy

Maintains

$49 → $45

2025-03-05

Reason

Morgan Stanley

Michael Ulz

Price Target

$49 → $45

2025-03-05

Maintains

Buy

Reason

BMO Capital

Kostas Biliouris

Buy

Maintains

$67 → $25

2025-03-04

Reason

BMO Capital

Kostas Biliouris

Price Target

$67 → $25

2025-03-04

Maintains

Buy

Reason

Goldman Sachs

Richard Law

Strong Sell

Maintains

$6 → $4

2025-03-04

Reason

Goldman Sachs

Richard Law

Price Target

$6 → $4

2025-03-04

Maintains

Strong Sell

Reason

Goldman Sachs

Richard Law

Strong Sell

Initiates

2025-02-11

Reason

Goldman Sachs

Richard Law

Price Target

2025-02-11

Initiates

Strong Sell

Reason

Goldman Sachs analyst Richard Law initiated coverage of Silence Therapeutics with a Sell rating and $6 price target.

HC Wainwright & Co.

Patrick Trucchio

Strong Buy

Reiterates

$75

2025-02-03

Reason

HC Wainwright & Co.

Patrick Trucchio

Price Target

$75

2025-02-03

Reiterates

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Silence Therapeutics PLC (SLN.O) is -9.17, compared to its 5-year average forward P/E of -14.80. For a more detailed relative valuation and DCF analysis to assess Silence Therapeutics PLC 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-14.80

Current PE

-9.17

Overvalued PE

-0.90

Undervalued PE

-28.70

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-6.87

Current EV/EBITDA

-1.69

Overvalued EV/EBITDA

-1.08

Undervalued EV/EBITDA

-12.67

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair

5Y Average PS

28.02

Current PS

14.84

Overvalued PS

55.67

Undervalued PS

0.37

Financials

Annual

Quarterly

FY2025Q1

YoY :

-99.10%

142.00K

Total Revenue

FY2025Q1

YoY :

+439.00%

-28.41M

Operating Profit

FY2025Q1

YoY :

+1099.17%

-28.53M

Net Income after Tax

FY2025Q1

YoY :

+900.00%

-0.20

EPS - Diluted

FY2025Q1

YoY :

-79.13%

-12.31M

Free Cash Flow

FY2025Q1

YoY :

-24.57%

61.97

Gross Profit Margin - %

FY2025Q1

YoY :

-73.89%

-77.31

FCF Margin - %

FY2025Q1

YoY :

+132780.62%

-20.09K

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

184.4K

Volume

6-9

Months

0.0

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

0.0

Volume

Months

6-9

700.0K

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

SLN News & Events

Events Timeline

2025-06-12 (ET)

2025-06-12

16:03:42

Silence Therapeutics presents additional Phase 1 data highlighting Divesiran

2025-05-08 (ET)

2025-05-08

08:12:29

Silence Therapeutics reports Q1 EPS (20c), consensus (41c)

2024-12-09 (ET)

2024-12-09

06:44:37

Silence Therapeutics announces additional results from SANRECO study

News

9.0

06-12Newsfilter

Silence Therapeutics Presents Additional Phase 1 Data Highlighting Promise of Divesiran as the Potential First-in-Class siRNA Treatment for Polycythemia Vera

4.0

05-09Benzinga

Chardan Capital Maintains Buy on Silence Therapeutics, Lowers Price Target to $35

5.0

05-06Newsfilter

Silence Therapeutics Welcomes Tim McInerney to Board of Directors